Lifileucel is a cell therapy commercialized by Iovance Biotherapeutics, with a leading Pre-Registration program in Metastatic Melanoma. According to Globaldata, it is involved in 18 clinical trials, of which 6 were completed, 8 are ongoing, 1 is planned, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Lifileucel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Lifileucel is expected to reach an annual total of $740 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Lifileucel (LN-144) is under development for the treatment of relapsed/refractory metastatic melanoma, recurrent head and neck cancer squamous cell carcinoma and non-small cell lung cancer. The therapeutic candidate is administered through intravenous route. It is developed as a ready to infuse autologous cellular immunotherapy product and contains adoptive cellular immunotherapy regimen. The therapeutic candidate consists of autologous tumor infiltrating lymphocytes (TILs) isolated from the patient’s tumor further expanded and then infused back to the patient enabling the patient robust immune response.
Iovance Biotherapeutics Overview
Iovance Biotherapeutics (Iovance) is a biotechnology company that focuses on the development and commercialization of novel immunotherapy products for treating various cancers. It develops products based on its tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidates include lifileucel is an autologous, ready-to-infuse cell therapy indicated for the treatment of melanoma and metastatic cervical cancer; and LN-145 for the treatment of head and neck cancer. The company also focuses on investigating TIL therapy for treatment of a various types of cancer. It has Iovance Cell Therapy Center (iCTC) in Philadelphia for the manufacture of the tumor infiltrating lymphocytes (TIL). The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.
The operating loss of the company was US$398.9 million in FY2022, compared to an operating loss of US$342.7 million in FY2021. The net loss of the company was US$395.9 million in FY2022, compared to a net loss of US$342.3 million in FY2021. The company reported revenues of US$0.5 million for the third quarter ended September 2023, an increase of 97.1% over the previous quarter.
For a complete picture of Lifileucel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.